Abstract
Non-small cell lung cancer (NSCLC) patients with epithermal growth factor receptor (EGFR) mutations can be treated with EGFR-tyrosine kinase inhibitor......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
